Difference between revisions of "Teniposide (Vumon)"
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute lymphocytic leukemia]] | *[[Acute lymphocytic leukemia]] | ||
| + | *[[Central nervous system (CNS) cancer]] | ||
| + | *[[Small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 02:26, 23 June 2013
Also known as VM-26.
General information
Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Teniposide (Vumon) patient drug information (Chemocare)[3]
- Teniposide (Vumon) patient drug information (UpToDate)[4]